Drugs / CBT-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03049852 | Apr 2017 → Apr 2018 | pterygium | Cloudbreak Therapeutics, LLC | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05456425 | Jun 2022 → Dec 2026 expected | pterygium | Cloudbreak Therapeutics, LLC | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-06 | Santen Gmbh | Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium santen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03049852 ↗ |
| Route | Other | “single ocular drug dose at Day 1 in the eye with primary pterygium” NCT03049852 ↗ |